Modern Pharmaceutics for Cardiovascular Diseases

Although various non-pharmaceutical strategies addressed to the primary prevention of cardiovascular diseases such as tobacco control policies, reducing the consumption of harmful food, and increasing physical activity still represent a key strategy, often they are not sufficient. Moreover, despite...

Disgrifiad llawn

Wedi'i Gadw mewn:

Manylion Llyfryddiaeth
Fformat:	Online
Iaith:	Saesneg
Cyhoeddwyd:	MDPI - Multidisciplinary Digital Publishing Institute 2024
Pynciau:	aspirin coronary artery disease prevention gastric protection micronization collagen cogrinding arterial hypertension HTN nuclear factor erythroid factor 2-related factor 2 Nrf2 oxidative stress antioxidant atherosclerosis pharmacotherapy emergent therapeutics natural anti-atherosclerotic products lipids lipoproteins small dense LDL cholesterol prevention therapy inflammation colchicine NLRP3 inflammasome coronary artery disease acute coronary syndrome heart failure contractility calcium cardiomyocyte myofilament HDAC inhibitor antifibrotic strategies cardiac fibrosis cardiovascular diseases fibrosis pathways therapeutic strategies regenerative medicine cell-free secretomes paracrine factors single-cell RNA sequencing serine protease inhibitor endothelial barrier renin-angiotensin-aldosterone system RAAS angiotensin-converting enzyme-2 ACE2 angiotensin 1-7 Ang (1-7) COVID-19 long-term effects angiotensin receptor–neprilysin inhibitor sodium-glucose co-transporter-2 inhibitors soluble guanylate cyclase activator cardiac myosin activation autonomic modulation SGLT2i empagliflozin NHE1 NHE11 sodium channel thema EDItEUR::M Medicine and Nursing
Mynediad Ar-lein:	ONIX_20240514_9783036599809_49
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Byddwch y cyntaf i adael sylw!

Modern Pharmaceutics for Cardiovascular Diseases

Eitemau Tebyg